Ovarian cancer is one of the most dangerous types of cancer that affects women. This cancer causes abnormal cell development in the ovaries, which can infiltrate or harm other body components such as the abdominal layers, the lining of the colon and bladder, lymph nodes, and liver. The early stages of ovarian cancer are linked with a few nonspecific symptoms that worsen as the malignancy progresses. Inflating, pelvic discomfort, belly puffiness, and loss of appetite are among the symptoms.
Ovarian cancer is a very rare disease when compared to other varieties, but the risk is higher in women who have ovulated more frequently throughout their lives, which can also include females who have never produced a child and those who began ovulating at a young age. According to the American Cancer Society, inherited hereditary risk accounts for around 10% of ovarian cancer incidences. Women who carry BRCA1 or BRCA2 gene mutations have a 50% probability of getting breast or ovarian cancer. Ovarian carcinoma is the most prevalent kind of ovarian cancer, accounting for 95% of occurrences worldwide.
The rising incidence of ovarian cancer patients in recent years is providing a highly favorable environment for the expansion of the ovarian cancer medications market. According to the American Cancer Society, about 22,280 new instances of ovarian cancer were reported in 2016, resulting in 14,240 fatalities in the United States. According to statistics from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, there has been an increase in all new cancer cases, with ovarian cancer accounting for 1.3 percent of the incidence rate and 2.4 percent of all associated deaths in 2016. The frequency of new ovarian cancer cases is 11.9 per 100,000 women, with a total mortality rate of 7.5 per 100,000 women. According to World Cancer Research Fund International statistics, the country with the highest rate of ovarian cancer is Fiji, where the age-standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria, where the rates are 14.2 and 14.0, respectively. The United Kingdom ranks eighth, with an age-standardized rate per 100,000 of 11.7. Around 58 percent of ovarian cancer cases are detected in emerging nations, with Africa and the Asia Pacific having the highest incidence rates. In the United Kingdom, around 46 percent of women diagnosed with ovarian cancer survive for five years or longer after the disease's inception. According to the Australian Government's Cancer Australia, 1,580 new ovarian cancer cases are expected to be detected in 2017, accounting for 2.5 percent of all new cancer cases in the country. In 2017, 1,047 people are expected to die as a result of this. As a result, shortly, the ovarian cancer medications sector is projected to acquire substantial traction in developed regions.